This study demonstrates that STAC3 gene analysis should be included in the diagnostic work up of patients of any ethnicity presenting with congenital myopathy, in particular if a history of MHlike episodes is reported. While the precise pathomechanism remains to be elucidated, our functional characterization of STAC3 variants revealed that defective ECC is not a result of Ca V 1.1 sarcolemma mislocalization or impaired STAC3-Ca V 1.1 interaction.
INTRODUCTION
Excitation-contraction coupling (ECC) is a process in which consecutive events lead from the depolarization of the muscle fiber membrane to increased cytosolic Ca 2+ release and initiation of muscle contraction. ECC occurs at specialized structures, termed triads, composed of a T-tubule and two lateral sacs of sarcoplasmic reticulum. The two major components of the ECC protein complex are the L-type voltagesensitive Ca 2+ channel (DHPR) and the sarcoplasmic reticulum Ca 2+ release channel RyR1 (Rios & Pizarro, 1991) . Although the role of DHPR and RyR1 in ECC has been extensively investigated, the precise regulatory mechanism underlying the mechanical coupling in skeletal muscle ECC and whether additional protein components are required is currently not entirely understood.
SH3 and cysteine-rich domain-containing protein 3 (STAC3; MIM# 615521) is essential for muscle contraction by facilitating ECC through a not completely understood mechanism (Horstick et al., 2013; Nelson et al., 2013) . STAC3 (Uniprot# Q96MF2) is specifically expressed in skeletal muscle (Bower et al., 2012; Horstick et al., 2013; Reinholt, Ge, Cong, Gerrard, & Jiang, 2013) , it is localized to the triads (Horstick et al., 2013; Nelson et al., 2013) , and interacts with RyR1 and the DHPR complex (Horstick et al., 2013) . More recently it was shown that STAC3 interacts with the Ca V 1.1 II-III loop (Polster, Nelson, The relevance of STAC3 in coupling the membrane depolarization to Ca 2+ release from the sarcoplasmic reticulum has been demonstrated using mouse and zebrafish models. Homozygous Stac3 knockout mice (KO) are paralyzed and die shortly after birth due to hypoxia as a result of paralyzed respiratory muscles (Nelson et al., 2013) , a phenotype similar to other animal models with disrupted ECC (Flucher, Phillips, & Powell, 1991; Nishi, 1995) . The complete lack of Stac3 in the spontaneous zebrafish mutant mi34 led to an aberrant locomotor phenotype and lethality of fish at the larval stage (Horstick et al., 2013) . Notably, the skeletal muscles from zebrafish and mouse Stac3-null animals displayed null (Nelson et al., 2013; Reinholt et al., 2013) or significantly reduced (Cong, Doering, Mazala, et al., 2016; Horstick et al., 2013) ability to contract following membrane depolarization. In the mutant animals neither the contractile apparatus nor RyR1 function appeared directly affected as addition of RyR1 agonists, such as 4-CMC or caffeine, were able to induce muscle contraction with similar force magnitude compared to the wild-type animals (Horstick et al., 2013; Nelson et al., 2013) . Defects in the nervous system were also unlikely since tactile stimulation induced synaptic responses in the mutant mi34 zebrafish (Horstick et al., 2013) . These data indicated that the abolished ability of stac3-null muscles to contract in response to depolarization was a result of defective ECC caused by the lack of Stac3.
The role of STAC3 in ECC has further been investigated in several recent studies. In heterologous cells (tsA201) Stac3 has been shown to be important for the trafficking of Ca V 1.1 (the pore-forming subunit of DHPR) to the plasma membrane (Polster, Perni, Bichraoui, & Beam, 2015) . Subsequent studies from the same group and others, however reported that in Stac3 KO myotubes, the failure of ECC was not a result of a trafficking defect of Ca V 1.1. Albeit at reduced levels, Ca V 1.1 was present on the plasma membrane but was not able to generate ECC Ca 2+ currents (Linsley, Hsu, Wang, & Kuwada, 2017; Polster, Nelson, Olson, & Beam, 2016) . The ECC was only restored after expression of the WT Stac3, demonstrating that Stac3 is important for the functional link between Ca V 1.1 and RyR1 (Linsley, Hsu, Wang, et al., 2017; Polster et al., 2016) .
The first report linking variants in STAC3 to a human disorder described a homozygous missense STAC3 variant p. (Trp284Ser) as causative for Native American myopathy (NAM; MIM# 255995; Horstick et al., 2013) . NAM is an autosomal recessive disorder found in the Lumbee Indian population of North Carolina and characterized by congenital muscle weakness, delayed motor development, susceptibility to malignant hyperthermia (MH), multiple joint contractures, short statue, scoliosis, and distinctive facial features such as ptosis, palate abnormalities, and long and narrow face (Stamm et al., 2008) .
Recently, recessive variants in STAC3 have been reported in patients with features overlapping Carey-Fineman-Ziter and Moebius syndrome (Grzybowski et al., 2017; Telegrafi et al., 2017) .
Here, we describe 18 patients carrying STAC3 pathogenic variants, the largest cohort of patients with STAC3-related congenital myopathy studied up to now. Importantly, the patients investigated here were not of Native American origin. Seventeen patients, of African, Middle Eastern, Afro-Caribbean, Comorian, and South American descent, carried the previously described homozygous NAM p.Trp284Ser STAC3 variant and one patient, of African/Afro-Caribbean descent, was compound heterozygous for the NAM variant in one allele and a novel c.997-1G > T splice site variant in the other allele.
MATERIALS AND METHODS

Ethical approval
Informed consent was obtained from all patients or from their parents or legal guardians. The study was approved by the Health Research Authority, NRES Committee East of England--Hatfield (REC 13/EE/0398) and National Institute of Neurological Disorders and Stroke, National Institutes of Health (12-N-0095).
Whole exome and Sanger sequencing
Whole exome sequencing (WES) was carried out in the probands from families PN1, PN3, PN9, PN10, and PN12. Targeted panel sequencing of known congenital myopathy genes was performed in the probands from families PN4, PN5, PN6, PN7, PN8, and PN11. Sanger sequencing was used to identify the STAC3 c.851G > C p.(Trp284Ser) variant in the affected cases from PN2.
Validation of the STAC3 variants and segregation analysis in family members were carried out using Sanger sequencing.
The novel STAC3 c.997-1G > T variant identified in PN5 has been submitted to Leiden Open Variation Database (www.LOVD.nl/STAC3)
Muscle histology
Muscle biopsies, taken from cases PN2D, PN3A, PN4, PN5, PN7, PN8, and PN12, were processed using standard histochemical stains previously described (Dubowitz, Sewry, & Oldfors, 2013) . Electron microscopic analyses were done in samples from cases PN5, PN7, and PN8.
Muscle magnetic resonance imaging (MRI)
Muscle MRI of the lower limbs by conventional T1 weighted sequences was performed in patients PN1, PN2A, PN2B, and PN4.
Immunofluorescent analysis
The primary antibodies used for the immunofluorescent analysis in cryosections from muscle biopsies were anti-RyR1 (ab2868, Abcam plc.) and anti-Cav1.1 (SC-8160, Santa Cruz, CA).
Confocal immunohistochemistry on myotubes was performed as previously described (Bachmann et al., 2017 ).
Western blotting
Protein extracts (30 g) from muscle biopsies were separated on pre- 
Molecular modeling
The molecular modeling of the p.(Trp284Ser) STAC3 was based on the nuclear magnetic resonance (NMR) structure of the first SH3 domain of Stac protein (Protein Data Bank accession code 2DL4). For the analysis of the effect of c.997-1G > T variant we used homology modeling of the STAC3 tandem SH3 domains carrying the deleted IVVQ amino acids and the crystal structure of human STAC1 tandem SH3 domains (6B25). The modeling was performed using Chimera visualization system (Pettersen et al., 2004) and Modeller (Sali & Blundell, 1993) .
Calcium measurements
Primary muscle cells were cultured as previously described (Bachmann et al., 2017; Censier, Urwyler, Zorzato, & Treves, 1998) . Statistical analysis was performed using the Student's t-test for paired samples or using analysis of variance test (ANOVA) when more than two groups were compared. Origin computer program (Microcal Software, Inc., Northampton, MA) was used for statistical analysis and dose response 
Co-immunoprecipitation
Protein extracts from muscle biopsies were solubilized and clarified.
Antibodies against Ca V 1.1 (sc-8160, Santa Cruz Biotechnology) or mouse IgG1 (GTX35014, GeneTex, Irvine, CA) were used. The solubilized muscle homogenates were incubated with Protein G-Sepharose and centrifuged. The bead pellets were loaded on an acrylamide gel, transferred onto nitrocellulose membrane and incubated with anti-STAC3 antibody (20392-1-AP, Proteintech Group). (Table 1) .
RESULTS
Identification of patients carrying STAC3 variants
Clinical features of cohort members
Detailed clinical information was available for 18 patients (12 families) with confirmed STAC3 variants (Table 1) more rapidly progressive that led to early death in two of them. These patients were not available for assessment and were therefore not included in the study.
Onset was at birth in all cases. Clinical severity ranged from a more severe prenatal/neonatal onset, to a milder slowly progressive, congenital myopathy phenotype, as documented in at least three children.
Polyhydramnios was recorded in three pregnancies and reduced fetal movements were noted in three additional pregnancies. The majority of the patients presented with hypotonia at birth and talipes (unior bilateral). Neck, elbows, wrists, fingers, or toes contractures were noted in six infants. Ten patients had cleft or high palate, one infant had a bifid uvula and an elevated right hemidiaphragm (PN5). Four infants presented with low birth weight. Feeding difficulties at birth and/or in infancy were documented in 15 patients. Eight infants had a variable degree of respiratory difficulties at birth and in the first days or life, with one (PN5) suffering severe perinatal asphyxia and cardiac arrest.
At last assessment, all patients were able to walk at least for short distances. All patients show mild to moderate, proximal more than distal upper and lower limb weakness, with axial weakness in 12 of them.
Lower leg muscle atrophy was observed in 11 patients. Ptosis and facial weakness was present in all patients, while none had ophthalmoplegia.
Contractures, in particular of fingers and ankles, were reported in 14 patients. Joint laxity was documented in seven patients, three of whom without associated contractures (PN6A-B-C). Scoliosis, kyphosis, and spinal rigidity were reported in 11 patients. Eight individuals showed dental malocclusion, malar hypoplasia, and jaw prominence (Figure 2 ).
Respiratory compromise was reported in eight patients. At the time of last assessment, four children received noninvasive ventilatory support. During infancy, 13 children had failure to thrive, and six needed nasogastric tube or gastrostomy feeding. Recurrent bradycardia and ventricular hypertrophy (resolved after age 1 year) were reported in two patients. Six children had speech delay or dysarthria and seven had documented hearing loss. Seven of the 11 male patients had cryptorchidism.
Malignant hyperthermia
Adverse reaction to anesthetics was reported in 10 patients after general anesthetics (GA). Detailed description of the full course of MH is available for patient PN5. Following five uneventful GAs, at a GA at age 6 months, because of difficult intravenous access, inhalational induction of anesthesia (with sevoflurane 8%, nitrous oxide 50%, and oxygen 50%) was carried out until successfully securing intravenous access approximately 45 min later. During this period, upper limb tone increased, end-tidal carbon dioxide increased, and attempts were made to increase minute ventilation manually. Heart rate had initially dropped from 164 bpm to 139 bpm at induction, but after 50 min induction was 208 bpm with a mean blood pressure of 53 mmHg. One hour after induction, core temperature was 39.6 • C, and both upper and lower limb tone was markedly increased. Dantrolene was given and vital signs immediately improved with steady decrease in heart rate, temperature, and reduction of muscle tone. Post-event biochemistry failed to detect myoglobinuria, raise in serum creatine kinase (CK), or potassium. The highest CK levels were 69 IU/L at 14 h post event.
PN6A had CK levels of about 600 IU/L and normal myoglobin levels after the MH-like event. Normal post-event CK and myoglobin levels were documented in two further patients.
Muscle MRI findings
Muscle MRI demonstrated slightly asymmetric, distal more than proximal, posterior more than anterior involvement, with semimembranosi muscles being the most affected. Asymmetric involvement of biceps femoris and semitendinosus muscles was noted in patient PN2D only (Figure 2c(iii) ). In the lower legs, tibialis anterior (TA) and posterior compartment muscles were relatively preserved in patient PN1 (Figure 2c(i) ), while patient PN2D showed a mild asymmetric involvement of the TA muscle (Figure 2c(iii) , bottom). Asymmetric lower leg involvement, in particular of the soleus muscle, was also observed in patient PN2A (Figure 2c (ii), bottom).
Histopathological features
Muscle biopsies from quadriceps from patients PN2D (taken at 9 years), PN3A (at 8 years), PN4 (at 1 year), PN5 (at 1 month), PN7 (at 2 months), and PN8 (at 3 months) showed myopathic changes ( Figure 3 ).
All biopsies showed variation in fiber size, no excess fat or connective tissue (Figure 3a ,b) with predominance of type I/slow myosin fibers in most (Figure 3c-f) . Although both fiber types showed variation in size, the smaller fibers were frequently type I/slow myosin fibers. Some biopsies also showed occasional fibers with internal nuclei, whorled and split fibers. Some very small fibers expressed fetal myosin, but not developmental myosin, suggesting that they were not regenerating fibers. These very small fibers expressing fetal myosin occur in a number of myopathic conditions and are currently of unknown origin (Dubowitz, Sewry, & Oldfors, 2013) .
Electron microscopy analysis showed myofibrillar loss, irregular and broken Z-lines with mini-core areas with disrupted sarcomeres (Figure 3g,h ). Mitochondria were of variable size, shape, and distribution. Swollen sarcoplasmic reticulum was present in some samples. The structure of triads appeared preserved, but the T-tubule component was often prominent and a little swollen.
STAC3 variants affect ECC and RyR1-mediated calcium release
To investigate the functional consequences of the detected STAC3 variants, we studied Ca 2+ homeostasis in myotubes from STAC3 patients.
Primary myoblasts were available from patients PN2D and PN5, however, cells from patient PN2D failed to differentiate and form multi- trol (10.6 ± 0.6 mM) and PN5 myotubes (12.7 ± 1.2 mM). However, the peak Ca 2+ in response to 4-CMC was significantly reduced (Figure 4c) as was the KCl-induced Ca 2+ release, which was reduced to approximately 10% of that observed in control myotubes (Figure 4d ). 
Cellular localization of
Effect of p.(Trp284Ser) and c.997-1G > T variants on STAC3 protein structure
The guanine to cytosine transversion at position c.851 (c.851G > C), observed in the patients, results in a substitution of the highly conserved tryptophan (Trp) with serine (Ser). Trp284 is located in the first SH3 domain of STAC3. The SH3 domains have been found in signaltransducing adaptor proteins (Mayer & Baltimore, 1993) and likely serve as anchoring sites for recruitment of substrates or mediate the formation of large protein complexes (Morton & Campbell, 1994) . The ligand-binding site of the SH3 domains is a hydrophobic surface with three shallow grooves formed by highly conserved aromatic residues, one of which is Trp284. These conserved aromatic residues are important for peptide binding as they establish hydrophobic interactions with key residues in the SH3-binding ligands (Lim & Richards, 1994;  Zafra-Ruano & Luque, 2012). 
DISCUSSION
In this study we report 18 patients of non-Native American ethnicity affected by congenital myopathy of variable severity due to recessive STAC3 variants. In childhood, the patients at the severe end of the clinical spectrum developed progressive contractures, scoliosis, and significant feeding and respiratory difficulties. Patients with the milder form often showed improvement of respiratory and feeding difficulties with age.
A recognizable facial "Gestalt", with weakness, ptosis, downslanting palpebral fissures, downturned corners of the mouth, and high-arched and/or cleft palate, specifically guided diagnosis in four families. Weakness was predominantly axial and proximal, static, or slowly progressive. Cryptorchidism was reported in almost half of the male patients.
Interestingly, a high number of patients had hearing loss (mostly conductive) and speech delay. As STAC3 is not expressed in the heart, the observation of cardiac problems in two individuals is likely to be unrelated. Long-term follow-up and description of further patients with STAC3 variants will clarify this issue.
Adverse reaction to anesthetics was common. Where detailed documentation was available, myoglobinuria, high increase in CK or potassium levels were absent and the onset of symptoms was more gradual. "Classic" MH often occurs rapidly with subsequent cardiovascular collapse and almost invariably results in post-event laboratory findings, indicating significant muscle breakdown (raised CK, urine The phenotype of this cohort overlaps with that previously reported in STAC3 patients but also expands the clinical spectrum. We observed patients with rather severe congenital presentations, with pterygium, feeding, and respiratory complications. One patient with severe presentation (PN5) was compound heterozygous for the recurrent NAM and a novel splice site variant. Similarly, three other reported previously patients with a more severe phenotype carried variants other than the recurrent NAM variant (frameshift or splice site variants; Grzybowski et al., 2017; Telegrafi et al., 2017) . However, it is worth noting that a degree of clinical variability is also observed among patients with homozygous NAM variant and among members of the same family, suggesting that factors other than the type of variants could contribute to the phenotypic variability.
The majority of the families included in this study were of known African, Afro-Caribbean, or Middle Eastern descent. The descent of the Lumbee Native American tribe is controversial, but has been speculated to include an admixture of Native Americans, European settlers, and African Americans (Zhang et al., 2015) . The observation of the NAM variant in various populations often of African descent could point toward a common ancestor of possible African origin. Interestingly, Telegrafi et al. (2017) found that the NAM variant was not in linkage with the same haplotype in their two families, implying that these variants originated from unrelated mutational events. Further studies and haplotype analysis might help to further clarify this point. activators. In the PN5 myotubes, application of the direct RyR1 agonist 4-CMC (Zorzato, Scutari, Tegazzin, Clementi, & Treves, 1993) induced lower Ca 2+ release compared to that observed in control myotubes. This is in contrast to results of that demonstrated that in Stac3 −/− mouse myotubes the peak calcium transient, induced by 5 mM 4-CMC and 25 mM caffeine, were similar to controls. It should be pointed out however, that 5 mM 4-CMC is a supramaximal concentration that may activate calcium release by RyR3 and/or other intracellular channels, which are also expressed in mouse myotubes (Ward et al., 2000) . The calcium peak in response to caffeine was reportedly similar in myotubes from stac3 −/− zebrafish and controls (Linsley, Hsu, Groom, et al., 2017 ; of note in the supplementary Figure 5 , the peak calcium induced by caffeine is reduced by about 25%), but in stac3 NAM fibers, the peak calcium response was significantly enhanced, with no change in the EC 50 for caffeine.
Our results in patient myotubes also showed no shift in sensitivity to either KCl or 4-CMC-mediated Ca 2+ release in cells harboring mutant STAC3. These findings suggest that the cellular events underlying the MH-like reactions appear to be different from those underlying "clas- A role of STAC3 in regulating Ca V 1.1 trafficking and localization to the sarcolemma has been shown (Polster et al., 2015) . However, our data in STAC3 patient myotubes demonstrated that both Ca V 1.1 and RyR1 were present and co-localized correctly in the patient's cells, indicating that the pathomechanism of STAC3 variants is not through impaired Ca V 1.1 trafficking. The data is in agreement with studies on mouse Stac3 NAM myotubes in which ECC was impaired without the membrane targeting of Ca V 1.1 being affected (Polster et al., 2016) .
As STAC3 has been shown to be a part of the DHPR complex and to stably interact with Ca V 1.1 Horstick et al., 2013; Linsley, Hsu, Groom, et al., 2017) , we hypothesized that the defective ECC in STAC3 patients was a result of impaired binding to Ca V 1.1. Nevertheless, co-immunoprecipitation of STAC3 with Ca V 1.1 in patient and control muscle samples pulled down STAC3 to equal extent and demonstrated that the protein interaction between STAC3 and Ca V 1.1 was not significantly affected by the STAC3 variants. In agreement, Campiglio and Flucher (2017) identified that the interaction between STAC3 and Ca V 1.1 is through a protein-binding pocket in the C1 domain of STAC3, and the p.(Trp284Ser) variant does not impair the stable STAC3-Ca V 1.1 interaction. An additional STAC3-Ca V 1.1-binding site has been identified in a recent study, which demon-strated that STAC3 interacts with the Ca V 1.1 linker connecting transmembrane domains II-III (Wong King Yuen et al., 2017) . While the p.(Trp284Ser) variant did not cause misfolding of the STAC3 protein, it abolished the interaction with the Ca V 1.1 II-III loop, which was previously identified as essential for the Ca V 1.1-RyR1 functional interaction (Grabner et al., 1999) . This additional interaction could lead to loss of the functional interaction with RyR1 and possibly could explain the impaired ECC in STAC3 patients.
In conclusion, in view of our results, the recently published data describing STAC3 variants in patients of non-Native American ethnicity, and the rather homogenous clinical presentations in patients of different ethnicities, we propose to name this condition as STAC3-related congenital myopathy, to highlight its wider distribution. STAC3 gene analysis should be included in the diagnostic work up of patients of any ethnicity presenting with a congenital myopathy, in particular if a history of MH is reported. While the precise underlying pathomechanism remains to be elucidated, functional characterization of p. (Trp284Ser) in myotubes and muscle biopsy samples from STAC3 patients demonstrated that the defective ECC is not a result of Ca V 1.1 sarcolemma mislocalization or impaired STAC3-Ca V 1.1 interaction. 
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